Proving Innovation Globally through Media and Academia

From clinical milestones to high-impact publications, discover the innovative journey of ProGen as we redefine the future of biologics.

NEWS
PUBLICATIONS

Scientifically Validated Publications and Posters

Explore our proprietary protein engineering technology validated by leading global journals.

progen-img-34ADA2026Efficacy
ADA2026-PG-102

Extended-Interval PG-102 Demonstrates Glycemic Efficacy With Favorable Gastrointestinal Tolerability and Body Composition Effects in Type 2 Diabetes: A Phase 2a Study

progen-img-34Endo-Poster-RT-114-v3
ENDO2025-RPG-102

Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines

progen-img-348.EASD2025–PG-102
EASD2025-PG-102
Decoupling Glycemic Control from Weight Loss in Advanced Type 2 Diabetes using a Bispecific GLP-1/GLP-2 Agonist with Favorable Human Tolerability
progen-img-347.EASD2025-PG-102
EASD2025-PG-102
PG-102, a Bispecific GLP-1/GLP-2 Fc Fusion Protein, Outperforms Peptide Agonist and Fc Fusion Combination in Preclinical Models and Shows Dose-dependent Weight Loss in Obese Subjects
progen-img-346.EASD2025-PG-102
EASD2025-PG-102
Weekly PG-102 Plus Bimagrumab Enhances Net Muscle Gain Compared to Daily Semaglutide-Based Regimens
progen-img-345.ADA2025-PG-110
ADA2025-PG-110
PG-110, a Novel Bispecific Antibody Targeting ActRII and Myostatin, Enhances Fat-Specific Weight Loss and Improves Bone Health in Combination with GLP-1 Agonist Therapy
progen-img-344.ADA2024_1874-LB
ADA2024-PG-102

PG-102, a Bivalent GLP-1RGLP-2R Agonist, Protects ß-Cell Mass and Enhances Glucose Uptake, Showing Superior Glycemic Control over Semaglutide, Tirzepatide, and Retatrutide in Obese db/db Mice

progen-img-343.ADA2024_1859-LB
ADA2024-PG-102
Safety, Tolerability, and Pharmacokinetics of PG-102, a Novel Bivalent GLP-1R/GLP-2R agonist, in Single Ascending Dose Trial and Population PK Modeling : Insights into Potentially Monthly Dosing
progen-img-342.EASD2023-PG-102
EASD2023-PG-102

Improved Body Composition and Glycemic Control with Bispecific GLP-1R/GLP-2R Agonist Compared to GLP-1R/GIPR Dual Agonist in Mouse Models of Obesity without and with T2D

progen-img-341.ADA2023–PG-102
ADA2023-PG-102
The effect of bispecific GLP-1R/GLP-2R agonist on visceral fat loss and systemic LPS level compared with GLP-1R/GIPR and GLP-1R/GLP-2R dual agonists in DIO mouse model
progen-img-353.Nature Communications (2026)
Nature Communi-
cations (2026)

Clinical Translation of PG-102
A bispecific GLP-1/GLP-2 receptor agonist demonstrating superior glycemic control and favorable tolerability from preclinical models to a phase 1 clinical trial for advanced type 2 diabetes.

progen-img-352.Nature Communications (2022)
Nature Communi-
cations (2022)

Discovery of IgETrap
(ProGen’s Fc backbone)
A proprietary fusion protein combining the FcεRIα receptor with an IgD/IgG4 hybrid Fc domain to minimize IgG1-mediated side effects.

progen-img-351.Hepatology(2021)
Hepatology
(2021)

Discovery of PG-105
(PG-102 prototype)
A long- acting dual agonist of GLP- 1 and GLP- 2 receptors is a promising therapeutic strategy to treat NAFLD/NASH

VIDEO

Visualizing the Future of
Next Generation Biologics

tire-team-pic1-2tire-team-pic2-2

2023 PHARM EDAILY Corporate Presentation
- ProGen CEO Jong-Gyun Kim

tire-team-pic1-2tire-team-pic2-2

2024 8th PHARM EDAILY Global Pharmaceutical Conference
[PG-102, a Bispecific GLP-1/GLP-2 Receptor Agonist For the Treatment of Metabolic Diseases]
- ProGen Chief Medical Officer Kun-Ho Yoon

tire-team-pic1-2tire-team-pic2-2

PG-102 – Differentiated Metabolic Therapy
(GLP-1/GLP-2 Dual Agonist)